Viking Therapeutics (VKTX) Other Non-Current Assets (2014 - 2026)
Viking Therapeutics' (VKTX) quarterly Other Non-Current Assets came in at $33000.0 in Q1 2026, down 28.26% year-on-year from $46000.0 in Q1 2025, and down 28.26% quarter-over-quarter from $46000.0 in Q4 2025.
Viking Therapeutics (VKTX) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Viking Therapeutics has disclosed Other Non-Current Assets across 13 years of filings, most recently posting $33000.0 for Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $33000.0, down 28.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $33000.0 (down 28.26% YoY), and the FY2025 annual result was $46000.0, changed 0.0% from the prior year.
- Other Non-Current Assets came in at $33000.0 for Q1 2026 at Viking Therapeutics, down from $46000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $46000.0 in Q3 2024 to a low of $33000.0 in Q1 2022.
- The 5-year median for Other Non-Current Assets is $33000.0 (2022), against an average of $37588.2.
- Across the five-year window, Other Non-Current Assets jumped 39.39% in 2024 and dropped 28.26% in 2026, its largest moves.
- Viking Therapeutics' Other Non-Current Assets stood at $33000.0 in 2022, then changed by 0.0% to $33000.0 in 2023, then jumped by 39.39% to $46000.0 in 2024, then changed by 0.0% to $46000.0 in 2025, then fell by 28.26% to $33000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $33000.0 (Q1 2026), $46000.0 (Q4 2025), and $46000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Viking Therapeutics | 3.50 Bn | 3.50 Bn | - | 33,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33,000.00 |
| Dec 31, 2025 | 46,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Jun 30, 2025 | 46,000.00 |
| Mar 31, 2025 | 46,000.00 |
| Dec 31, 2024 | 46,000.00 |
| Sep 30, 2024 | 46,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | 33,000.00 |
| Dec 31, 2023 | 33,000.00 |
| Sep 30, 2023 | 33,000.00 |
| Jun 30, 2023 | 33,000.00 |
| Mar 31, 2023 | 33,000.00 |
| Dec 31, 2022 | 33,000.00 |
| Sep 30, 2022 | 33,000.00 |
| Jun 30, 2022 | 33,000.00 |
| Mar 31, 2022 | 33,000.00 |
| Dec 31, 2021 | 33,000.00 |
| Dec 31, 2020 | 29,000.00 |
| Sep 30, 2020 | 29,000.00 |